IPO News Archive
Drug developer Merrimack postpones IPO
Merrimack Pharmaceuticals, which uses its Network Biology system to discover and develop cancer treatments, postponed its IPO on Wednesday due to poor market conditions. The Cambridge, MA-based company was founded in 1993 and currently has five candidates in clinical programs. J.P. Morgan had been selected to lead manage the IPO.